First gene therapy approved for fatal neuron disease in children

Orchard Therapeutics hopes its metachromatic leukodystrophy drug will save lives — and establish this form of gene therapy as profitable.

March 18, 2024 Check out STAT+

Sponsored By

Christine Kao/STAT STAT+ | As Humira biosimilars take over the market, CVS has created a new ploy: the drug 'rebate credit' With Humira biosimilars taking over the market, the PBM found a crafty way to keep as much money as possible. By Bob Herman STAT+ | FDA approves first gene therapy for a fatal neuron disease in children Orchard Therapeutics hopes its treatment for metachromatic leukodystrophy will save lives — and establish this form of gene therapy as profitable. By Jason Mast STAT+ | As AI marches into medicine, investors eye security, privacy startups Investors are looking to build out a parallel ecosystem of startups focused on AI governance, data security and privacy, and compliance. By Mohana Ravindranath Mike Reddy for STAT The harms of adverse childhood experiences are well-known. But positive experiences can affect future health, too We talk a lot about adverse childhood experiences in health care. I wish we could talk more about positive ones, too. By Jennifer Adaeze Okwerekwu The latest twist in John Green's anti-tuberculosis story: working with governments After goading companies to make TB treatments more affordable, John Green embarks on a private-public partnership. By Katherine MacPhail EPA bans asbestos, a deadly carcinogen still in use decades after partial ban The new rule from the EPA would ban chrysotile asbestos, the only ongoing use of asbestos in the United States. By Associated Press Michael Dwyer/AP STAT+ | The Boston area built a ton of lab space. Now many of those buildings are opening empty The region's supply of life-science real estate exploded just as the once-booming industry hit a slow patch. Now what? By Catherine Carlock — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser